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We have read with interest the recent debate between Drs Varma and Epstein regarding the 
grading of intraductal carcinoma of the prostate.1 Unfortunately, the arguments as presented do 
little to abate the confusion surrounding this so-called diagnostic entity.
We disagree with the definition of IDCP as provided in the introduction.1 IDCP is marked by the 
presence of malignant, not atypical cells, in pre-existing prostatic ducts, as the latter can apply to 
high grade prostatic intraepithelial neoplasia and so-called atypical intraductal proliferation.  
As described IDCP is simply as its name suggests – infiltration of ducts by aggressive carcinoma 
and is therefore analogous to intravascular or lymphatic invasion by tumour. The designation 
IDCP is unfortunate as it has some similarities to ductal carcinoma in situ of the breast, which as 
the terminology clearly states, is a non-invasive lesion. 
Studies have appeared identifying IDCP as an in situ lesion in the absence of invasive malignancy 
and much of the debate regarding the validity of grading IDCP surrounds the existence of this 
entity. In the reports relating to so-called in situ IDCP there are concerns relating to 
completeness of sampling of the specimens.2 Two studies, where it is claimed that there was 
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perhaps 3 cases as it is uncertain if the cases reported in the latter study were the same as those 
in the initial report).3,4 Interestingly these cases are all from one institution and it is surprising 
that, if IDCP is a precursor lesion, many other cases have not been discovered. Despite this it has 
been stated in the Bluebook that IDCP is found without invasive carcinoma in approximately 10% 
of radical prostatectomy specimens following (the detection of) pure IDCP on biopsy.  These 
observations are based upon a sample of only 21 cases3 and do not accord with our collective 
experience.
In one of the studies noted above, the molecular genetics of in situ IDCP was investigated and, 
while the results were very incomplete, it was shown that the features were similar to those of 
high grade invasive cancer.4 These results were interpreted to imply that in situ IDCP was an 
aggressive tumour. It would be equally valid to imply that the results confirmed that the tumour 
foci were, in fact, invasive carcinoma that had invaded a duct. 
We would take issue with the claim that it is spurious that historical studies incorporated IDCP 
into grading of prostate cancer. Clearly this is not true, as IDCP was not recognized by the 
authors of many of the earlier studies, including Gleason himself. In the WHO Bluebook it is 
noted that IDCP may be found in 17% of prostatectomies.5 An important observation in relation 
to this is that the majority of comedonecrosis seen in prostatic adenocarcinoma is IDCP,6 and as 
such it is apparent that many cases of high grade tumour would be under-graded if IDCP was not 
incorporated.  This is particularly relevant if the recommendation to severely limit 
immunohistochemical staining for basal cells is followed. 
It has been suggested that to include IDCP in the grading of otherwise low grade cancer would 
have a significant effect on patient management and in some circumstances patients could be 
candidates for active surveillance. This is in direct contradiction of the findings
of a survey involving a group of urological pathologists.7 In the survey it was agreed that IDCP 
was an independent driver of prognosis and a major contraindication for active surveillance. We 
would concur with this latter recommendation, as IDCP is simply an invasive high grade cancer 
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the percentage of pattern 4 and 5 tumour present. Surely, if IDCP is included in the dimensions of 
the tumour, confers an adverse prognosis and excludes patients from conservative 
management,7 the logical course would be to include it in the final grade which would have the 
same treatment and prognostic implications.
In an international consensus report, authored by 31 prostate cancer experts which lays out a 
detailed argument against the recommendation that IDCP not be graded, it was acknowledged 
that IDCP is an aggressive duct invasive tumour that should be reported, graded and treated as 
such.2 It was also noted that the lack of consistency in diagnostic criteria has contributed to 
confusion regarding the nature of IDCP as there is overlap with the features of prostatic 
intraepithelial neoplasia.2 We contend that if IDCP is present it should be included in the tumour 
grade. If the features do not permit definitive assessment then the lesion should be reported as 
atypical intraductal proliferation and a repeat biopsy recommended. 
References
1. Varma M, Epstein JI. Head to head: should intraductal component of invasive prostate cancer 
be graded? Histopathology in press.
2. Samaratunga H, Delahunt B, Egevad L, et al. Intraductal carcinoma of the prostate is an 










This article is protected by copyright. All rights reserved
3. Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on 
needle biopsy. Emphasis on radical prostatectomy findings. J Urol. 2010;184:1328-1333.
4. Kahni F, Wobker SE, Hicks JL et al. Intraductal carcinoma of the prostate in the absence of high 
grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched 
with oncogenic driver mutations. J Pathol. 2019;249:79-89.
5. Moch H, Humphrey PA, Ulbright TM, Reuter VE editors. . WHO Classification of tumours of the 
Urinary System and male genital organs. Lyon: IARC Press; 2016.
6. Fine SW, Ai-Ahnadi HA, Chen YB, et al. Comedonecrosis revisited : strong association  with 
intraductal carcinoma of the prostate. Am J Surg Pathol. 2018; 42:1036-41.
7. Gandhi JS, Smith S, Paner GP, et al. Reporting practices and resource utilization in the era of 
intraductal carcinoma of the prostate. A survey of genitourinary specialists.  Am J Surg 
Pathol. 2020;44:673-680.
Acknowledgement
BD was the author of the letter and all co-authors contributed editorial revisions. 
A
cc
ep
te
d
 A
rt
ic
le
